Abstract: The invention generally relates to methods of treating a central nervous system related disorder in a human subject, the method comprising providing a pharmaceutical composition to a human subject having a central nervous system disorder, wherein the pharmaceutical composition is an oral formulation that comprises a compound of Formula (I): at a dose between 5 mg and 90 mg.

Abstract: Described herein is a method for determining an effective dose of a composition for inhibiting fatty acid amide hydrolase activity in vivo, by first administering to a subject a dose of a test composition, and subsequently assessing if the level of a fatty acid amide in the subject increases. Also described, is a method for optimizing therapeutic efficacy for treatment of anxiety, depression, pain, or a metabolic disorder by increasing or decreasing a dose of a fatty amide hydrolase inhibitor according to a patient's fatty acid amide levels. In addition, pharmaceutical compositions are described, which contain fatty acid amide hydrolase inhibitors effective for increasing a FAA level in a patient.